Company intelligence / Profile preview

906 CMVI

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

906 CMVI is a biotechnology company focused on the development of novel therapeutic agents for the treatment of Cytomegalovirus (CMV) infections. The company's primary focus is on advancing a specific small molecule inhibitor, often referred to as 906, which targets CMV replication. By leveraging proprietary research into viral protein interactions, 906 CMVI aims to provide more effective and less toxic alternatives to current antiviral therapies. The company is currently in the pre-clinical stage, conducting studies to validate the efficacy and safety profile of its lead candidate.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on 906 CMVI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 906 CMVI.

Explore the full profile